MindWalk Holdings Corp. has filed European patent application No. EP26187897.9 for high-dimensional data structures for biological subsequences and property inference. The filing, announced on July 6, 2026, aims to protect the enriched biological representation architecture that supports its HYFT Technology, ReefIQ biological context layer, and LensAI reasoning workflows. This development is significant for stakeholders as it secures intellectual property for the company's core technology used in drug discovery, targeting a market where spending on AI in drug discovery is projected to grow from approximately US$5 billion in 2026 to more than US$8 billion by 2030.

The patent covers a multi-dimensional biological representation layer organized around MindWalk’s HYFT pattern anchors. This model-agnostic context layer is designed to support ReefIQ, LensAI, and customer-selected AI workflows. These tools retrieve, compare, and reason over connected, traceable biology, facilitating advanced drug discovery processes. The application is described as additive to MindWalk's foundational HYFT patent (WO 2020/161344), protecting a distinct computational layer built on the original foundation rather than a re-filing of it.

MindWalk’s HYFT Technology serves as the foundation for its product suite. The ReefIQ biological context layer and LensAI reasoning workflows rely on this architecture to deliver analytical capabilities. The company states that LensAI is in contracted, recurring arrangements with life-sciences customers, and the filing is intended to protect a layer those deployments can build on as data and program experience accumulate.

The filing of the European patent application marks a step in MindWalk's strategy to expand its intellectual property portfolio. By securing rights to its high-dimensional data structures, the company aims to strengthen its competitive position in the market for AI-driven biological analysis. The company frames the timing against a clear architectural lesson emerging in agentic AI for life sciences: frontier models alone are not enough, and domain-specific context is required for real scientific workflows.

MindWalk says it has begun to demonstrate the approach in active programs, with results the company frames as preclinical. In dengue, the company has reported preclinical binding-level data in which a HYFT-identified target informed immunogen design. In influenza, MindWalk has disclosed a HYFT-defined functional constraint observed across broad influenza A and B datasets. These programs remain preclinical, and the company states that additional studies are required to assess neutralization, safety, durability, clinical translation, regulatory path, and commercial potential.

MindWalk Holdings Corp., a Bio-Native AI company, has been added to the Russell 3000E Index, effective after the U.S. market close on June 26, 2026. The inclusion is part of the FTSE Russell June 2026 semi-annual Russell US Indexes Reconstitution. Membership was reconfirmed in index data published on June 29, 2026. This addition expands the company's visibility among institutional investors and broadens its eligibility for index-tracking funds managing approximately $12.2 trillion in benchmarked assets.

Index Reconstitution Details

The Russell 3000E Index is FTSE Russell's broadest measure of the U.S. equity market, covering up to the 4,000 largest U.S.-domiciled public companies by market capitalization. Inclusion is determined using market capitalization as of the rank date, with no application or fee required. The reconstitution process occurs semi-annually in June and December, ensuring the index accurately reflects the current market landscape.

Key Dates

Jennifer Bath, Ph.D., Chief Executive Officer and President of MindWalk Holdings Corp., stated that being added to the index is a meaningful visibility milestone. She noted that it places the company in front of a broader set of institutional investors and signals that the market is starting to price the infrastructure layer beneath biological AI.

MindWalk's stock trades on the NASDAQ under the ticker symbol HYFT. The company builds BioIntelligence infrastructure, integrating AI, data, and advanced wet lab capabilities. Its core technology includes HYFT fingerprints spanning sequence and structural biology, forming a continuously evolving biological representation of 660 million patterns and 25 billion relationships.